GLP-1 coverage decisions were the easy part. Two years in, employers are facing the harder question: what happens when people stop the medication. Discontinuation is common, weight often returns, and the spend starts over. For benefits leaders heading into 2027 renewals, the risk is no longer access; it is durability.
This session gives HR and benefits teams a practical way to protect that investment. You will learn how to build support that holds after the prescription ends, how to serve GLP-1 users and non-users under one program, and which signals at 6 and 12 months show whether early results are becoming lasting workforce outcomes.
